Sign Out
Hypersensitivity to the active substances or to any of the excipients listed in Description.
Pregnancy and lactation (see Use in Pregnancy & Lactation).
Active liver disease or unexplained persistent elevations in serum transaminases.
Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC approximately 5 fold or greater) (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, nefazodone, and drugs containing cobicistat) (see Precautions and Interactions).
Concomitant administration of gemfibrozil, ciclosporin, or danazol (see Precautions and Interactions).
In patients with HoFH, concomitant administration of lomitapide with doses > 10/40 mg Co-Ezetimibe TEVA (see Dosage & Administration, Precautions and Interactions).
